Department of Dermatology, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Korea.
Australas J Dermatol. 2023 Aug;64(3):408-412. doi: 10.1111/ajd.14074. Epub 2023 May 8.
Chronic hand and foot eczema (CHFE) is a common inflammatory disorder that generally lasts for over 3 months. If it is intractable to topical agents, systemic immunomodulators can be considered; however, they are not suitable for long-term management because of their adverse effects. Baricitinib is an oral Janus kinase inhibitor that has been approved for the treatment of moderate-to-severe atopic dermatitis. However, its effect on CHFE has rarely been described. Herein, we report nine cases of recalcitrant CHFE that were treated with baricitinib after an inadequate response to low-dose ciclosporin. All patients had more than moderate improvement within 2-8 weeks without serious adverse effects.
慢性手足湿疹（CHFE）是一种常见的炎症性疾病，通常持续超过 3 个月。如果外用药物治疗无效，可以考虑使用全身性免疫调节剂；但是，由于其不良反应，它们并不适合长期管理。巴瑞替尼是一种口服 JAK 抑制剂，已被批准用于治疗中重度特应性皮炎。然而，其对 CHFE 的疗效很少有报道。在此，我们报告了 9 例对低剂量环孢素治疗反应不佳的难治性 CHFE 患者，在使用巴瑞替尼治疗后，这些患者在 2-8 周内均有明显改善，且无严重不良反应。
